Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.47 |
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | KIF5B | P33176 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29677789 | 0.98 | HTT (0.50) | HTTMAPK1LMNARAB9ATUBB1 | |
| SCHEMBL282059 | 0.98 | HTT (0.50) | HTTMAPK1LMNARAB9ATUBB1 | |
| SCHEMBL7783072 | 0.83 | CYP17A1 (0.57) | HTTMAPK1LMNARAB9ATUBB1 | |
| SCHEMBL30988808 | 0.83 | SLC6A4 (0.39) | HTTMAPK1LMNARAB9ATUBB1 | |
| SCHEMBL7110169 | 0.83 | KDM4E (0.41) | HTTLMNATUBB1EGFRRET | |
| SCHEMBL23259191 | 0.82 | GAA (0.44) | HTTMAPK1LMNARAB9AEGFR | |
| SCHEMBL265537 | 0.80 | KDM4E (0.42) | HTTLMNATUBB1EGFRRET | |
| SCHEMBL29365368 | 0.80 | KDM4E (0.42) | HTTLMNATUBB1EGFRRET | |
| SCHEMBL17070605 | 0.80 | KDM4E (0.42) | HTTLMNATUBB1EGFRRET | |
| SCHEMBL1256865 | 0.79 | CA2 (0.54) | MAPK1ACHETDP1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100548950-C | Process for preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS INC (US) | 2009-10-14 | — | — | CN | claimed |
| CN-1759084-A | Process for preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS INC (US) | 2006-04-12 | — | — | CN | claimed |
| EP-2675526-B1 | NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2017-02-01 | — | — | EP | disclosed |
| US-9102688-B2 | Sulfonaminoquinoline hepcidin antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2015-08-11 | — | — | US | disclosed |
| US-20150191452-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-09 | — | — | US | disclosed |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2014-12-11 | — | — | US | disclosed |
| EP-2675526-A1 | NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS | Vifor (International) AG (CH) | 2013-12-25 | — | — | EP | disclosed |
| WO-2012110603-A1 | NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | WO | disclosed |
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
| CN-100548950-C | Process for preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS INC (US) | 2009-10-14 | — | — | CN | disclosed |
| CN-101391972-A | Process of preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS INC (US) | 2009-03-25 | — | — | CN | disclosed |
| EP-0826680-A1 | Dihydronaphthalene and naphthalene compounds, intermediates, formulations, and methods | ELI LILLY AND COMPANY (US) | 1998-03-04 | — | — | EP | disclosed |
| EP-0826670-A1 | Naphthalene compounds, intermediates, formulations, and methods | ELI LILLY AND COMPANY (US) | 1998-03-04 | — | — | EP | disclosed |
| EP-0341686-B1 | Novel halogen-containing ester compounds, and their intermediates, and method of producing the same as well as liquid crystal compositions containing the same and light switching elements | JAPAN ENERGY CORP (JP) | 1994-08-17 | — | — | EP | disclosed |
| US-5098602-A | Aromatic ester derivatives and fluorophenol ketones | NIPPON MINING CO., LTD. (JP) | 1992-03-24 | — | — | US | disclosed |
| EP-0231853-B1 | OPTICALLY ACTIVE CARBOXYLIC ACID DERIVATIVES AND LIQUID CRYSTALLINE COMPOSITIONS COMPRISING THEM | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1990-11-22 | — | — | EP | disclosed |
| US-4914224-A | HIGH-SPEED RESPONSE, WIDE TEMPERATURE RANGE, CHIRAL SMECTIC PHASES | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1990-04-03 | — | — | US | disclosed |
| US-4911862-A | Aromatic carboxylic ester | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1990-03-27 | — | — | US | disclosed |
| EP-0341686-A2 | Novel halogen-containing ester compounds, and their intermediates, and method of producing the same as well as liquid crystal compositions containing the same and light switching elements | JAPAN ENERGY CORPORATION (JP) | 1989-11-15 | — | — | EP | disclosed |
| EP-0231853-A2 | Optically active carboxylic acid derivatives and liquid crystalline compositions comprising them | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1987-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | HAMP, SLC40A1, FTH1 | HTT 1327/4885MAPK1 2936/4885LMNA 4127/4885 |
| US-20150191452-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | HTT 501/4885MAPK1 2103/4885LMNA 3807/4885 |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | HAMP, SLC40A1, FTH1 | HTT 1327/4885MAPK1 2936/4885LMNA 4127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.